Dec 18, 2020

Featuring interviews with Drs Maha Hussain, Ursula Matulonis, Phillip A Phillip and Hope S Rugo on the following topics:

• PARP inhibitors for breast cancer — Hope S Rugo, MD (0:00)
• Case: A woman in her early 60s with dermatomyositis is diagnosed with ER-positive breast cancer and ovarian cancer and a germline BRCA1 mutation (36:48)
• DNA repair gene alterations and response to PARP inhibitors in breast cancer (40:26)
• PARP inhibitors in patients with advanced ovarian cancer (OC) — Ursula Matulonis, MD (46:46)
• Case: A woman in her mid-60s with advanced OC and a germline BRCA1 mutation achieves an excellent response to maintenance olaparib (1:06:04)
• Case: A woman in her early 60s with homologous recombination deficient advanced OC receives niraparib (1:07:54)
• Perspective on the use of neoadjuvant therapy for patients with OC; risks and benefits with PARP inhibitors for advanced OC (1:09:47)
• DNA repair and PARP inhibitors in pancreatic cancer — Philip A Philip, MD, PhD, FRCP (1:26:59)
• Case: A man in his mid-70s with locally advanced pancreatic cancer and a somatic BRCA1 mutation receives modified FOLFIRINOX followed by maintenance olaparib (1:51:12)
• Case: A man in his early 50s is diagnosed with metastatic pancreatic cancer, elevated bilirubin and mutations in BRCA1, APC, KRAS and p53 (2:00:10)
• Optimizing the use of PARP inhibition for prostate cancer (PC) — Maha Hussain, MD, FACP, FASCO (2:07:56)
• Case: A man in his late 60s with metastatic castration-resistant PC (mCRPC) and a germline BRCA2 mutation receives olaparib on the BRCAAway trial (2:30:35)
• Case: A man in his early 70s with mCRPC and a BRCA2 mutation achieves an excellent response to veliparib with abiraterone/prednisone on a clinical trial (2:33:46)
• Role of liquid biopsy in identifying mCRPC with BRCA1/2 mutations; ongoing trials investigating PARP inhibitors in PC (2:36:41)

CME information and select publications